Noted Vaccine Researcher and Leader Kate O'Brien Awarded Sabin's Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O'Brien, MD, MPH, for her research on the pneumococcal vaccine and leadership in global vaccine research and access, and its Rising Star Award to dedicated physician and public health specialist Livancliff Mbianke, MD, MPH, of Cameroon. The awards were presented at a ceremony in the National Academy of Sciences building in Washington D.C.
O'Brien is a pioneering global health leader whose innovative work in vaccine access and policy has transformed immunization programs worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Ottawa Citizen
14-05-2025
- Ottawa Citizen
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Article content Article content SAN DIEGO and TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) has been selected for oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. Article content The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. As reported prior, the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet, have demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up. Article content Details of the presentation are as follows: Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Session: Oral Presentations: Acute Myeloid Leukemia – Clinical Session Date and Time: Thursday, June 12, 2025, 5:00 – 6:15 pm CEST Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine Abstract #: S139 Article content Article content The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. Article content The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available.
Ottawa Citizen
14-05-2025
- Ottawa Citizen
Materials, Data, Landscapes, Space, and Wellbeing: Politecnico di Milano research supporting 7 Projects at the Biennale Architettura 2025
Article content MILAN, May 14, 2025 (GLOBE NEWSWIRE) — At the 19th International Architecture Exhibition – La Biennale di Venezia, taking place 10 May-23 November 2025, Politecnico di Milano will support seven projects addressing the challenges of contemporary architecture through an interdisciplinary lens. This year's event, curated by Carlo Ratti, is entitled 'Intelligens. Natural. Artificial. Collective.' and invites reflection on the forms of intelligence emerging from the interplay between space, technology, and society. Article content Article content Article content In this context, the presence of the Politecnico di Milano is reflected in the installations that foster dialogue between architecture, science, and innovation, engaging with themes such as sustainability, sensory perception, wellbeing, and new materials. Applied research, a cross-disciplinary outlook, and an emphasis on social impact form the common thread linking these projects, designed to enrich the global discourse on the future of architecture. Article content Politecnico di Milano's Rector, Donatella Sciuto said: 'The presence of the Politecnico di Milano as a supporter of several projects participating in the Biennale Architettura 2025 is part of one of the most prestigious cultural events on the Italian and international scene. The Biennale di Venezia, with its long-standing heritage and unrivalled prestige, is a hub of creativity where artists, architects, thinkers, and innovators converge and work together. It reflects the social, cultural, and technological transformations of our time, and the university finds itself mirrored in this setting as a driver of change. The university is a place of knowledge, where intelligence is nurtured, developed, and evolves and where new areas of application and forms of expression are discovered. The theme chosen by Carlo Ratti is significant for us, as it is within this framework that architecture must imagine and bring to life new worlds.' Article content Article content Biennale Architettura 2025 curator and Politecnico di Milano professor Carlo Ratti said: 'The message of this Biennale is urgent – the built environment must adapt to a changing planet. Architecture is no longer a matter of form, but of survival. To address this challenge, it must evolve, drawing on all forms of natural, artificial, and collective intelligence at our disposal. This is why universities play such a crucial role in this year's Biennale, especially in a time when they are confronted by emerging forms of obscurantism. We are honoured to count Politecnico di Milano among our participants. I hope the Biennale can carry this message to Piazza Leonardo da Vinci and our current and future students. Architecture has the power to change the world, if we are brave enough to let it.' Article content The Politecnico di Milano supports the following projects participating in the Biennale Architettura 2025: Material Bank – Matters Make Sense is a project set up at the Corderie dell'Arsenale, presented by Ingrid Maria Paoletti and Stefano Capolongo (Department of Architecture, Built Environment and Construction Engineering, Politecnico di Milano), together with set designer Margherita Palli and Nobel Laureate Konstantin Novosëlov (National University of Singapore), awarded for his work on graphene. The project explores perception as a fundamental form of intelligence, linking innovative materials, sensory experience and the built environment. Inspired by the intertwined concepts of a labyrinth and a library, the installation, features interactive devices such as the Polimi_Sensing Core, which enables visitors to perceive their own heartbeat through reactive fabrics, prompting a reflection on the body as an environmental interface.
Ottawa Citizen
14-05-2025
- Ottawa Citizen
Hydreight Technologies to Present at Maxim Group's 2025 Virtual Tech Conference & the CEM Bermuda Capital Event
Article content VANCOUVER, British Columbia and LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. ('Hydreight' or the 'Company') (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform transforming mobile and telehealth services across the United States, today announced that Shane Madden, CEO of Hydreight, will be presenting at the following investor conferences in June 2025: Article content Article content Article content Hosted by: Maxim Group LLC Date: June 3–5, 2025 Presentation Time: Tuesday, June 3rd at 12:30 PM PT / 3:30 PM ET Location: Virtual (M-Vest Platform) Registration: Click here to attend Article content Maxim's 2025 Virtual Tech Conference explores how emerging growth companies are leveraging technologies such as AI and telehealth to shape the future of healthcare and other industries. Hydreight's presentation will highlight its national healthcare infrastructure, proprietary technology platform, and strategy to scale its direct-to-consumer and pharmacy verticals. Article content CEM Bermuda Capital Event Article content Hydreight will participate in one-on-one meetings with institutional and high-net-worth investors throughout the conference. Article content Hydreight recently reported audited financial results for the fiscal year ended December 31, 2024, achieving several financial and operational milestones: Article content Article content Please see SEDAR+ for the Company's audited annual consolidated financial statements and MD&A for the year ends. Article content In 2024, Hydreight expanded its offerings to include Liraglutide, NAD+, TRT, peptide therapies, and oral weight-loss medications. The Company also secured strategic partnerships with national health franchises and clinical experts, including The DRIPBaR and Dr. Franklin Joseph.
